Clinical Trial Update: A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects [Phase 1]

View source ↗

Summary

This Phase 1 trial in healthy subjects evaluated the bioequivalence between two insulin degludec/liraglutide formulations (B5 and V2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin Degludec/Liraglutide

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED